Loading clinical trials...

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention | Clinical Trials | Clareo Health

TERMINATEDPHASE3

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab

NCT01613482•Centre Oscar Lambret

View on ClinicalTrials.gov

Summary

Evaluate the survival without metastasis in patients treated by Trastuzumab in association with other chemotherapies for a breast cancer expressing HER2-NEU.

Eligibility

Age

18 - 70 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH)
•Visceral metastasis, only or multiple
•First line metastasis treatment by Trastuzumab in association with chemotherapy
•Good general conditions: OMS=\<2 or Karnofsky \>=70%
•Age \> 18 years and \< 70 years
•Life expectancy \>=3 mois
•No Trastuzumab since more of 6 months
•No cerebral metastasis (MRI)
•Efficacy contraception for women with genital capacities
•Consent signed by the patient

Exclusion Criteria

•Contraindication to IRM
•Psychiatric decease
•Prior cerebral radiotherapy,
•Geographical constraint, compromising the fallow of patients
•Infectious or other serious pathology, likely to stop the treatment
•Positive serology (HIV, hBC, hBS)
•Inclusion in an other clinical trial or in the 4 weeks before th inclusion
•Pregnant or breastfeeding women

Locations (26)

Centre Paul Papin

Angers, France

Centre Hospitalier

Boulogne-sur-Mer, France

Centre Maurice Tubiana

Caen, France

Centre G-François Baclesse

Caen, France

Centre Léonard de Vinci

Dechy, France

Centre Médical de Forcilles

Forcilles-attilly, France

Clinique des Ormeaux- Vauban

Le Havre, France

Centre Bourgogne

Lille, France

Centre Oscar LAMBRET

Lille, France

CHU Dupuytren

Limoges, France

Key Dates

Start Date

January 1, 2008

Primary Completion Date

August 1, 2009

Completion Date

January 1, 2012

Last Updated

March 16, 2026

Enrollment

ACTUAL participants

Conditions

Breast CancerMetastasisSur-expressing Her2-neu

Interventions

cerebral prophylactic radiation

RADIATION

Trastuzumab

DRUG

Other chemotherapy in association with Trastuzumab

DRUG

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer